Retrospective analysis of efficacy of trastuzumab in adjuvant treatment of HER 2 positive early breast cancer – single institution experience

Ban, Marija; Viculin, Jelena; Tomić, Snježana; Čapkun, Vesna; Strikić, Ante; Miše, Branka Petrić; Utrobičić, Ivan; Vrdoljak, Eduard

doi:10.4149/neo_2016_513

Cited by 6 publications

(6 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It effectively downregulates the PI3K/Akt and MAPK pathways, leading to improved response and survival rate of Her2-positive breast cancer patients. Furthermore, combining Trastuzumab with different chemotherapeutic agents, such as docetaxel or vinorelbine, reduced recurrence and death in breast cancer patients [66][67][68][69].…”

Section: Trastuzumab (Herceptin™)mentioning

confidence: 99%

Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials

Maennling

Tur

Niebert

et al. 2019

Cancers

158

109

View full text Add to dashboard Cite

The epidermal growth factor receptor (EGFR) family contains four transmembrane tyrosine kinases (EGFR1/ErbB1, Her2/ErbB2, Her3/ErbB3 and Her4/ErbB4) and 13 secreted polypeptide ligands. EGFRs are overexpressed in many solid tumors, including breast, pancreas, head-and-neck, prostate, ovarian, renal, colon, and non-small-cell lung cancer. Such overexpression produces strong stimulation of downstream signaling pathways, which induce cell growth, cell differentiation, cell cycle progression, angiogenesis, cell motility and blocking of apoptosis.The high expression and/or functional activation of EGFRs correlates with the pathogenesis and progression of several cancers, which make them attractive targets for both diagnosis and therapy. Several approaches have been developed to target these receptors and/or the EGFR modulated effects in cancer cells. Most approaches include the development of anti-EGFRs antibodies and/or small-molecule EGFR inhibitors. This review presents the state-of-the-art and future prospects of targeting EGFRs to treat breast cancer.

show abstract

Section: Trastuzumab (Herceptin™)mentioning

confidence: 99%

Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials

Maennling

Tur

Niebert

et al. 2019

Cancers

158

109

View full text Add to dashboard Cite

show abstract

“…It is currently the preferred surgical treatment for early breast cancer in Western countries [8][9][10][11] . The results of this study show that, by observing and comparing operative time and intraoperative blood loss between the study group and the reference group, the study group had shorter operative time and less intraoperative blood loss, p<0.05, with statistical significance.…”

Section: Resultsmentioning

confidence: 99%

Exploration into the Clinical Value of Breast-Conserving Therapy Combined with Sentinel Lymph Node Biopsy in the Treatment of Early Breast Cancer

Fang¹,

Gu²

2021

ijps

View full text Add to dashboard Cite

Fang et al.: Breast-Conserving Therapy Combined with Sentinel Lymph Node BiopsyTo observe and analyze the application effect of breast-conserving therapy combined with sentinel lymph node biopsy in the treatment of early breast cancer. We selected 120 patients with early breast cancer who were treated in our hospital as subjects. Immediately thereafter, the patients were divided into study group and reference group, each with 60 cases. Different treatment plans were performed. The reference group was treated with conventional surgical mastectomy and axillary lymph node dissection. The study group was treated with breast-conserving therapy combined with sentinel lymph node biopsy. The treatment results of the two groups were observed and compared. By observing intraoperative operative time and intraoperative blood loss of the two groups, the results showed the two were significantly less in the study group than the reference group, p<0.05. In comparison of the patients postoperative quality of life and breast cosmetic results, the study group was obviously superior to the reference group, p<0.05. In addition, comparison of postoperative local recurrence rate and distant metastasis rate revealed no significant difference and there was no statistical significance, p>0.05. Treatment of early breast cancer patients with breast-conserving therapy combined with sentinel lymph node biopsy can achieve relatively good results and can significantly improve patient's quality of life.

show abstract

“…In node-negative HER2+ BC patients, we know that the addition of trastuzumab to adjuvant chemotherapy reduces the risk of recurrence by approximately 40% and the risk of death by up to 30% ( 41 ). According to meta-analyses, the benefits of trastuzumab are independent of age, T and N stage, and hormone receptor status.…”

Section: Discussionmentioning

confidence: 99%

Management of HER2-Positive Early Breast Cancer in Italy: A Maze Presenting Opportunities and Challenges

et al. 2022

View full text Add to dashboard Cite

The management of human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer (BC) has changed in recent years thanks to the introduction of anti-HER2 agents in clinical practice as standard of care in the neoadjuvant setting. In this scenario, we probed the issue of which HER2-positive BC patients are eligible for neoadjuvant or for adjuvant treatment, since these therapeutic strategies seem to be mutually exclusive in clinical practice according to an Italian drug surveillance system. We reviewed both alternatives to establish which is more suitable, considering the anti-HER2 drugs available in Italy. Randomized clinical trials demonstrated a similar clinical benefit for chemotherapy administered as neoadjuvant therapy or adjuvant therapy. A meta-analysis, including 11,955 patients treated with neoadjuvant therapy, demonstrated an improvement in event-free survival (EFS) and overall survival (OS). Moreover, the recent APHINITY trial, analyzed at 6 years follow-up, demonstrated the superiority of the combination pertuzumab–trastuzumab versus trastuzumab–placebo in previously untreated patients. A greater benefit was found in patients with positive lymph nodes treated in the adjuvant setting. Our analysis underlines the need for a therapeutic decision-making algorithm, which is still unavailable, to support clinicians in identifying patients suitable for neoadjuvant or adjuvant therapy. Further prospective clinical trials should be performed in collaboration with other Italian Breast Cancer Centers to establish the best strategy to be adopted in early HER2+ BC.

show abstract

Retrospective analysis of efficacy of trastuzumab in adjuvant treatment of HER 2 positive early breast cancer – single institution experience

Cited by 6 publications

References 25 publications

Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials

Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials

Exploration into the Clinical Value of Breast-Conserving Therapy Combined with Sentinel Lymph Node Biopsy in the Treatment of Early Breast Cancer

Management of HER2-Positive Early Breast Cancer in Italy: A Maze Presenting Opportunities and Challenges

Contact Info

Product

Resources

About